Progressive ganglion cell loss and optic nerve degeneration in DBA/2J mice is variable and asymmetric.
BACKGROUND
Glaucoma is a chronic neurodegenerative disease of the retina, characterized by the degeneration of axons in the optic nerve and retinal ganglion cell apoptosis. DBA/2J inbred mice develop chronic hereditary glaucoma and are an important model system to study the molecular mechanisms underlying this disease and novel therapeutic interventions designed to attenuate the loss of retinal ganglion cells. Although the genetics of this disease in these mice are well characterized, the etiology of its progression, particularly with respect to retinal degeneration, is not. We have used two separate labeling techniques, post-mortem DiI labeling of axons and ganglion cell-specific expression of the betaGeo reporter gene, to evaluate the time course of optic nerve degeneration and ganglion cell loss, respectively, in aging mice.


RESULTS
Optic nerve degeneration, characterized by axon loss and gliosis is first apparent in mice between 8 and 9 months of age. Degeneration appears to follow a retrograde course with axons dying from their proximal ends toward the globe. Although nerve damage is typically bilateral, the progression of disease is asymmetric between the eyes of individual mice. Some nerves also exhibit focal preservation of tracts of axons generally in the nasal peripheral region. Ganglion cell loss, as a function of the loss of betaGeo expression, is evident in some mice between 8 and 10 months of age and is prevalent in the majority of mice older than 10.5 months. Most eyes display a uniform loss of ganglion cells throughout the retina, but many younger mice exhibit focal loss of cells in sectors extending from the optic nerve head to the retinal periphery. Similar to what we observe in the optic nerves, ganglion cell loss is often asymmetric between the eyes of the same animal.


CONCLUSIONS
A comparison of the data collected from the two cohorts of mice used for this study suggests that the initial site of damage in this disease is to the axons in the optic nerve, followed by the subsequent death of the ganglion cell soma.
Schlamp
Cassandra L
CL
Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA. clschlamp@wisc.edu
Li
Yan
Y
Dietz
Joel A
JA
Janssen
Katherine T
KT
Nickells
Robert W
RW
D000367:Age Factors; D000818:Animals; D002232:Carbocyanines; D002452:Cell Count / Q000379:methods; D016009:Chi-Square Distribution; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D018450:Disease Progression; D005901:Glaucoma / Q000150:complications; D051379:Mice; D008811:Mice, Inbred DBA; D008822:Mice, Transgenic; D009901:Optic Nerve Diseases / Q000209:etiology / Q000473:pathology*; D012162:Retinal Degeneration / Q000209:etiology / Q000473:pathology* / Q000503:physiopathology; D012165:Retinal Ganglion Cells / Q000473:pathology*; D013997:Time Factors; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism; D043743:Ubiquitin-Protein Ligase Complexes; D001617:beta-Glucosidase / Q000235:genetics / Q000378:metabolism
C035005:3,3'-dihexadecylindocarbocyanine; D002232:Carbocyanines; D004268:DNA-Binding Proteins; D014157:Transcription Factors; C486646:Fem1c protein, mouse; D043743:Ubiquitin-Protein Ligase Complexes; D001617:beta-Glucosidase